As Gulf bourses display mixed results, with investors on the lookout for new catalysts amid fluctuating oil prices and shifting global trade dynamics, attention turns to the potential of smaller market players. Penny stocks, a term that may seem outdated, still hold relevance as they often represent smaller or newer companies with significant growth potential. This article will explore three such stocks from the Middle East that combine financial strength with promising opportunities for investors seeking hidden value.
Top 10 Penny Stocks In The Middle East
| Name | Share Price | Market Cap | Rewards & Risks |
| Thob Al Aseel (SASE:4012) | SAR4.17 | SAR1.67B | ✅ 2 ⚠️ 1 View Analysis > |
| Keir International (SASE:9542) | SAR3.95 | SAR474M | ✅ 2 ⚠️ 3 View Analysis > |
| Alarum Technologies (TASE:ALAR) | ₪2.797 | ₪195.88M | ✅ 4 ⚠️ 2 View Analysis > |
| Terminal X Online (TASE:TRX) | ₪4.535 | ₪575.97M | ✅ 2 ⚠️ 1 View Analysis > |
| Oil Refineries (TASE:ORL) | ₪0.927 | ₪2.88B | ✅ 1 ⚠️ 2 View Analysis > |
| Tgi Infrastructures (TASE:TGI) | ₪2.207 | ₪164.07M | ✅ 2 ⚠️ 2 View Analysis > |
| Sharjah Cement and Industrial Development (PJSC) (ADX:SCIDC) | AED0.701 | AED426.39M | ✅ 2 ⚠️ 2 View Analysis > |
| Dubai National Insurance & Reinsurance (P.S.C.) (DFM:DNIR) | AED2.88 | AED332.64M | ✅ 2 ⚠️ 5 View Analysis > |
| E7 Group PJSC (ADX:E7) | AED1.00 | AED2.02B | ✅ 3 ⚠️ 2 View Analysis > |
| Dubai Investments PJSC (DFM:DIC) | AED2.38 | AED10.03B | ✅ 2 ⚠️ 3 View Analysis > |
Click here to see the full list of 93 stocks from our Middle Eastern Penny Stocks screener.
Let's explore several standout options from the results in the screener.
Gulf Pharmaceutical Industries P.S.C (ADX:JULPHAR)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Gulf Pharmaceutical Industries P.S.C., along with its subsidiaries, operates in the manufacturing and sale of medicines, drugs, and various pharmaceutical, cosmetic, and medical compounds across the United Arab Emirates, other GCC countries, and internationally with a market cap of AED1.59 billion.
Operations: The company's revenue is primarily derived from its Manufacturing segment, which generated AED864.9 million, and its Planet segment, contributing AED732.9 million.
Market Cap: AED1.59B
Gulf Pharmaceutical Industries P.S.C. has demonstrated significant financial improvement, becoming profitable over the past year with a net income of AED 140.9 million in Q1 2025, up from AED 1.9 million the previous year. The company maintains strong short-term asset coverage over both its short and long-term liabilities, and its debt is well managed with a satisfactory net debt to equity ratio of 4.8%. Despite low return on equity at 2.4%, earnings quality remains high, supported by stable weekly volatility and reduced debt levels from previous years, reflecting prudent financial management amidst growing revenues forecasted at 6.91% annually.
- Get an in-depth perspective on Gulf Pharmaceutical Industries P.S.C's performance by reading our balance sheet health report here.
- Understand Gulf Pharmaceutical Industries P.S.C's earnings outlook by examining our growth report.
Sinpas Gayrimenkul Yatirim Ortakligi (IBSE:SNGYO)
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Sinpas Gayrimenkul Yatirim Ortakligi, originally established as Sinpas Insaat in 2006 and transformed into a Real Estate Investment Partnership in 2007, operates in the real estate sector with a market capitalization of TRY15.08 billion.
Operations: The company generates revenue of TRY13.44 billion from its residential real estate developments segment.
Market Cap: TRY15.08B
Sinpas Gayrimenkul Yatirim Ortakligi has shown impressive earnings growth, with a 210.1% increase over the past year, outpacing its five-year average of 33.4%. The company's debt management is robust, evidenced by a net debt to equity ratio of 11.1%, and its operating cash flow comfortably covers debt obligations at 33.3%. However, interest coverage remains a concern at only 2.3 times EBIT. Despite large one-off gains impacting recent financial results and declining profit margins from last year, the company trades at an attractive price-to-earnings ratio of 2.9x compared to the broader market's 19.1x.
- Dive into the specifics of Sinpas Gayrimenkul Yatirim Ortakligi here with our thorough balance sheet health report.
- Examine Sinpas Gayrimenkul Yatirim Ortakligi's past performance report to understand how it has performed in prior years.
Alarum Technologies (TASE:ALAR)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Alarum Technologies Ltd. offers web data collection solutions across multiple regions including the Americas, Europe, Southeast Asia, the Middle East, and Africa, with a market cap of ₪195.88 million.
Operations: Alarum Technologies generates revenue from web data collection ($30.91 million), advertising services ($0.04 million), and consumer internet access ($0.87 million).
Market Cap: ₪195.88M
Alarum Technologies, with a market cap of ₪195.88 million, has demonstrated profitability with earnings of US$5.78 million for 2024, rebounding from a previous net loss. Its revenue streams are diversified across web data collection and consumer internet access. The company’s debt management is strong, with cash exceeding total debt and operating cash flow covering debt by over 900%. However, the stock remains highly volatile and faces legal challenges due to a class action lawsuit in the U.S., which could impact investor sentiment despite its solid financial footing and high return on equity at 21.9%.
- Unlock comprehensive insights into our analysis of Alarum Technologies stock in this financial health report.
- Assess Alarum Technologies' future earnings estimates with our detailed growth reports.
Taking Advantage
- Access the full spectrum of 93 Middle Eastern Penny Stocks by clicking on this link.
- Ready For A Different Approach? Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Gulf Pharmaceutical Industries P.S.C might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com